XML 146 R131.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Jun. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting [Abstract]                          
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic $ (5,647,000) $ (13,040,000) $ (9,107,000) $ (9,807,000) $ (14,625,000) $ (37,348,000) $ (203,521,000) $ (78,752,000)     $ (37,601,000) $ (334,246,000) $ (301,971,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted (5,647,000) (13,040,000) (9,107,000) (9,807,000) (14,625,000) (37,348,000) (203,521,000) (78,752,000)     (37,601,000) (334,246,000) (301,971,000)
Interest income                     407,000 2,633,000 3,406,000
Interest expense                     (25,425,000) (28,325,000) (14,555,000)
(Provision) benefit for income taxes                     (483,000) 2,368,000 22,795,000
Depreciation and amortization expenses                     (60,037,000) (60,835,000) (60,323,000)
Equity method investment impairment                     0 (47,133,000) 0
Gain on transfer of membership                     45,938,000 0 0
Loss on repayment of debt, net                     (21,343,000) 0 0
Loss on extinguishment of debt                     0 (4,789,000) 0
Impairment             (215,100,000) 0 $ (199,800,000) $ (215,100,000) 0 (215,100,000) (199,800,000)
Gain (loss) from equity method investees                     13,179,000 10,039,000 (9,465,000)
Gain (loss) on disposal of assets                     0 (698,000) 9,600,000
Change in fair value of contingent consideration and indemnification asset                     (13,281,000) (3,860,000) 3,997,000
Net loss attributable to non-controlling interests         (822,000) 822,000 0 0     0 0 3,609,000
Other income (expense), net                     (146,000) (118,000) (489,000)
Purchase accounting adjustments                     0 0 (1,915,000)
Repositioning costs                     (7,318,000) (1,275,000) 0
Stock-based compensation expense                     (16,711,000) (14,606,000) (15,618,000)
Severance costs                     (198,000) (8,986,000) (17,350,000)
Amortization of contract cost assets                     (476,000) (3,944,000) (2,876,000)
Strategy and shareholder advisory expenses                     (6,513,000) 0 0
Acquisition costs                     (4,194,000) (2,116,000) (10,769,000)
Gain (loss) from discontinued operations $ (8,700,000) [1] $ 0 $ 0 $ 1,383,000 $ (3,166,000) $ (1,135,000) $ (1,508,000) $ (265,000)     (7,317,000) [1] (6,074,000) [1] 1,613,000 [1]
Adjusted EBITDA                     $ 66,317,000 $ 48,573,000 $ (13,831,000)
[1] Includes $6.8 million loss on disposal of discontinued operations for the year ended December 31, 2021